William Blair reiterated their market perform rating on shares of Henry Schein (NASDAQ:HSIC – Get Rating) in a report published on Tuesday, PriceTargets.com reports. William Blair also issued estimates for Henry Schein’s Q4 2022 earnings at $1.23 EPS, FY2022 earnings at $4.83 EPS, Q1 2023 earnings at $1.15 EPS, Q2 2023 earnings at $1.14 EPS, Q3 2023 earnings at $1.21 EPS, Q4 2023 earnings at $1.42 EPS, FY2023 earnings at $4.92 EPS and FY2024 earnings at $5.29 EPS.
HSIC has been the topic of several other reports. Credit Suisse Group cut their price target on shares of Henry Schein from $100.00 to $90.00 and set an outperform rating on the stock in a report on Wednesday, August 3rd. Piper Sandler dropped their target price on shares of Henry Schein from $96.00 to $85.00 and set an overweight rating on the stock in a report on Monday, September 26th. StockNews.com initiated coverage on shares of Henry Schein in a report on Wednesday, October 12th. They set a buy rating on the stock. UBS Group raised shares of Henry Schein from a sell rating to a neutral rating and set a $80.00 target price on the stock in a report on Monday, August 8th. Finally, Evercore ISI dropped their target price on shares of Henry Schein to $83.00 in a report on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of Hold and an average price target of $84.67.
Henry Schein Trading Up 2.3 %
HSIC opened at $72.69 on Tuesday. The stock has a market capitalization of $9.85 billion, a PE ratio of 15.80, a P/E/G ratio of 1.95 and a beta of 0.78. The firm’s fifty day moving average price is $69.92 and its 200 day moving average price is $76.38. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.84 and a quick ratio of 0.95. Henry Schein has a 12-month low of $64.75 and a 12-month high of $92.68.
Henry Schein declared that its board has approved a stock repurchase program on Thursday, August 18th that permits the company to buyback $400.00 million in shares. This buyback authorization permits the company to buy up to 4% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.
Hedge Funds Weigh In On Henry Schein
Several institutional investors have recently modified their holdings of the company. Dark Forest Capital Management LP bought a new position in Henry Schein in the 2nd quarter valued at about $34,000. Ronald Blue Trust Inc. bought a new position in Henry Schein in the 2nd quarter valued at about $37,000. Ellevest Inc. grew its position in Henry Schein by 231.8% in the 3rd quarter. Ellevest Inc. now owns 564 shares of the company’s stock valued at $37,000 after buying an additional 394 shares in the last quarter. Venture Visionary Partners LLC bought a new position in Henry Schein in the 2nd quarter valued at about $46,000. Finally, Dupont Capital Management Corp grew its position in Henry Schein by 46.2% in the 1st quarter. Dupont Capital Management Corp now owns 611 shares of the company’s stock valued at $53,000 after buying an additional 193 shares in the last quarter. Institutional investors own 94.99% of the company’s stock.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
- Get a free copy of the StockNews.com research report on Henry Schein (HSIC)
- MarketBeat: Week in Review 10/31-11/4
- Is Hershey’s a Sweet Stock to Buy After a Post-Earnings Dip?
- Datadog Doesn’t Belong In The Doghouse
- Nikola Shares Fall Even As EV Maker Beats Q3 Expectations
- Mixed Results Actually Bring More Optimism than Risk for AMD
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.